CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Compugen Ltd (CGEN) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some bullish momentum and analysts have a positive outlook with a $4 price target, the company's recent financial performance is highly negative, with significant declines in revenue, net income, and EPS. Additionally, there are no recent news catalysts, and trading sentiment remains neutral. Given the investor's background and preference for long-term investment, it is better to wait for more favorable financial performance or stronger positive catalysts before considering an investment.
The stock shows bullish momentum with MACD above 0 and positively expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the RSI at 59.697 in the neutral zone. The price is near the first resistance level (R1: 1.791). However, the overall trend is not strongly established.
Analyst coverage initiated with a Buy rating and a $4 price target, citing the company's immuno-oncology pipeline and potential royalty streams.
Significant declines in financial performance in Q3 2025, including an 88.96% drop in revenue, a 646.94% drop in net income, and an 800% drop in EPS. No recent news or significant trading trends from hedge funds, insiders, or Congress.
Q3 2025 financials show a sharp decline in revenue to $1.891M (-88.96% YoY), net income to -$6.979M (-646.94% YoY), and EPS to -0.07 (-800% YoY). Gross margin also dropped significantly to 12.74% (-83.87% YoY).
H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing the company's immuno-oncology pipeline and potential royalty streams from AstraZeneca's estimated peak sales of over $5B.
